Cryo-28
Percutaneous
8-Probe System

The CryoCare® 8-probe system, is the latest innovation for Percutaneous Cryoablation from Endocare. The system combines ease of use with broad clinical application. The system controls up to eight probes that can be used independently or simultaneously for exceptional flexibility.

TempProbe™

This 18 gauge precision device monitors tissue temperatures with the ability to report temperatures within 2 degrees celsius.

## Products

<table>
<thead>
<tr>
<th>PROBE MODEL</th>
<th>SHAFT</th>
<th>ISOThERM (DIAMETER x LENGTH IN cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PERC-15</td>
<td>1.7MM</td>
<td>15CM</td>
</tr>
<tr>
<td>PERC-17</td>
<td>1.7MM</td>
<td>15CM</td>
</tr>
<tr>
<td>PERC-24</td>
<td>2.4MM</td>
<td>15CM</td>
</tr>
<tr>
<td>PERC-24L</td>
<td>2.4MM</td>
<td>15CM</td>
</tr>
<tr>
<td>R 3.8</td>
<td>3.8MM</td>
<td>13CM</td>
</tr>
<tr>
<td>R 3.8L</td>
<td>3.8MM</td>
<td>28CM</td>
</tr>
</tbody>
</table>

Isotherm data based on gelatin formula which approximates performance (±5 MM) in soft tissue at 10 minutes.

Corporate Office
201 Technology Drive
Irvine CA 92618

Phone 949.450.5400
Toll Free 800.418.4677
Fax 949.450.5300

E-mail: PerCryo@endocare.com

© 2006 Endocare, Inc. All Rights Reserved. Protected by U.S. Pat.No.'s 5,647,868; 5,800,487; 5,800,488; 6,074,412; 6,139,544; 6,251,105 and other U.S. and foreign patents pending.

PM-3352 Rev.B 03/06
PerCryo® Applications

RENAL TUMORS
- Allows for freezing into the collecting system.
- Should not effect long-term renal function and does not result in urinary extravasation or caliceal fistula formation.
- Ideal for exophytic, mixed and central lesions.
- Allows nephron-sparing treatments, independent of the local thermal characteristics of the target zone.

PULMONARY & THORACIC TUMORS
- Ability to freeze into the trachea and bronchi while minimizing potential complications.
- Nearly every location of the lung is treatable.
- Applicable for those patients with reduced lung function.

HEPATIC TUMORS
- Highly visible ice increases the ability to protect adjacent structures.
- Ability to treat peripheral or capsular lesions with minimal pain and discomfort.
- Ability to treat multi-focal and bi-lobar disease simultaneously or large lesions with multiple probes.

PALLIATIVE INTERVENTION
- Significant decrease in pain for bone metastases patients, without short-term pain increase found in other methods.
- Maintaining collagenous architecture of nerve endings may allow for immediate reduction in pain with associated metastatic disease.
- Treat large zones and geometrically difficult tumors in one treatment with multiple probes and high visibility in soft tissues.

Benefits of PerCryo Treatment

HIGHLY VISIBLE UNDER IMAGE GUIDANCE
PerCryo’s extreme visibility under image guidance may decrease the amount of mistreated tumor. Under CT imaging, the ice ball is visible with a 40 hounsfield unit drop in attenuation, and with ultrasound the ice is hypoechoic. Better monitoring during procedure results in higher verification of ablation zone.

LESS PAINFUL DURING & POST-PROCEDURE
PerCryo’s ice formation is a natural anesthetic. This allows treatment of a broad variety of patients with minimal procedure discomfort. This may simplify the patient’s sedation requirements, require less analgesic, and aid in a faster recovery time.

DOES NOT DESTROY COLLAGEN
PerCryo leaves tissue architecture intact. This allows for treatments near critical structures, such as the collecting system of the kidney or near the trachea. Sparing tissue architecture and allowing system functionality following treatment.

ICE PROPAGATION IS PREDICTABLE & REPRODUCIBLE
PerCryo’s reproducible ice growth and predictability of success, make for a very controllable procedure with potentially more consistent outcomes. Consistency of ice formation can be easily planned, then safely monitored.

MULTIPLE CRYOPROBES MAY BE USED SIMULTANEOUSLY
During PerCryo, multiple CryoProbes may be used simultaneously. This allows PerCryo to treat large ablation volume, as well as allow for treatment of multiple tumors treated concurrently. While a single CryoProbe may deliver a 4x6cm iceball, up to eight probes can be used at once, while being controlled independently.

INDUSTRY’S LARGEST PORTFOLIO OF APPROVED USES
PerCryo has the largest scope of approved on-label uses of any treatment currently for ablation. Including approval for ablation of cancerous or malignant tissue, ablation of benign tumors, palliative intervention, and ablation of cancerous lesions.

Endocare Cryoablation
The evolution of cryoablation techniques, from the emergence decades ago to the recent success of new technologies has increased and enhanced the options available to physicians worldwide. Endocare’s unique approach, of precise technology and accurate control have improved intervention in the treatment of benign and malignant tumors throughout the body. Endocare’s cryoablation experience in open, laparoscopic and percutaneous applications spans up to 10-years of data in prostate, kidney, and liver. The continued advances, in both method and technology, of cryoablation applications point to a significant difference in the future of oncology and the prospects for its patients.